Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bioton S.a. (BIO.WA)
Ozarów Mazowiecki, PL
Bioton S.A. operates as a biotechnology company, engaged in the creation, production, distribution, and commercialization of a diverse array of pharmaceuticals, medicinal preparations, and active pharmaceutical ingredients. Its primary focus is on diabetes management, offering products such as recombinant human and conventional insulin, alongside oral anti-diabetic medications. The company's portfolio extends to include dietary supplements, blood glucose monitoring strips, and over-the-counter solutions for diabetics. Key insulin products include Gensulin N, Gensulin R, and Gensulin M30, available in vials and cartridges. Complementing these are advanced delivery and monitoring systems like the GensuPen 2 automatic injection device and the GensuCare glucometer for diabetes monitoring, alongside essential needles. Bioton S.A. distributes its offerings across numerous international markets, including Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. Beyond its core product activities, the company also undertakes advertising, advisory services, and general corporate management. Founded in 1989, its headquarters are situated in Ozarów Mazowiecki, Poland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.36% | -3.91% | +0.24% | -3.91% | +5.56% | +5.82% | -0.48% | +14.36% | -21.43% | -57.99% | -88.50% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+36.0% ★ Q1'26: -25.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+121.9% ★ Q1'26: +11.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+1.7% Q1'26: -7.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+5.1% ★ Q1'26: -11.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+1.4% ★ Q1'26: -3.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.08× Q1'26: 13.88× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
404.41M
est: 414.10M (-2.3%)
|
277.61M
est: 414.10M (-33.0%)
|
361.65M
est: 434.84M (-16.8%)
|
241.17M
est: 457.62M (-47.3%)
|
202.03M
est: 195.00M (+3.6%)
|
221.79M
est: 196.00M (+13.2%)
|
163.03M
est: 190.00M (-14.2%)
|
233.16M
est: 198.10M (+17.7%)
|
181.64M
est: 187.10M (-2.9%)
|
207.76M
est: 202.10M (+2.8%)
|
282.52M
est: 260.00M (+8.7%)
|
266.00M
266.00M – 266.00M
+2.3% YoY
|
285.00M
285.00M – 285.00M
+7.1% YoY
|
| EBITDA |
-495.70M
est: 99.42M (-598.6%)
|
21.42M
est: 99.42M (-78.5%)
|
22.17M
est: 104.40M (-78.8%)
|
52.69M
est: 109.87M (-52.0%)
|
-124.52M
est: 46.82M (-366.0%)
|
76.26M
est: 47.06M (+62.1%)
|
45.09M
est: 45.62M (-1.2%)
|
58.56M
est: 47.56M (+23.1%)
|
31.26M
est: 44.92M (-30.4%)
|
32.57M
est: 42.19M (-22.8%)
|
52.89M
est: 54.28M (-2.6%)
|
55.53M
55.53M – 55.53M
+2.3% YoY
|
59.49M
59.49M – 59.49M
+7.1% YoY
|
| EBIT |
-534.56M
est: 29.80M (-1,894.0%)
|
-11.17M
est: 29.80M (-137.5%)
|
-9.95M
est: 31.29M (-131.8%)
|
22.97M
est: 32.93M (-30.3%)
|
-155.57M
est: 14.03M (-1,208.7%)
|
47.04M
est: 14.10M (+233.5%)
|
13.45M
est: 13.67M (-1.6%)
|
24.15M
est: 14.25M (+69.4%)
|
-3.72M
est: 13.46M (-127.7%)
|
-3.72M
est: 8.03M (-146.3%)
|
14.42M
est: 10.33M (+39.6%)
|
10.57M
10.57M – 10.57M
+2.3% YoY
|
11.33M
11.33M – 11.33M
+7.1% YoY
|
| Net Income |
-522.86M
est: 11.31M (-4,723.3%)
|
-28.57M
est: 11.31M (-352.6%)
|
-7.27M
est: 31.03M (-123.4%)
|
26.27M
est: 43.97M (-40.3%)
|
-126.69M
|
33.92M
|
2.88M
|
1.42M
|
2.28M
est: 3.43M (-33.8%)
|
-15.66M
est: -6.01M (-160.5%)
|
3.39M
est: -858.6K (+495.2%)
|
12.02M
12.02M – 12.02M
+1,500.0% YoY
|
22.32M
22.32M – 22.32M
+85.7% YoY
|
| SGA |
143.35M
est: 140.44M (+2.1%)
|
146.42M
est: 140.44M (+4.3%)
|
157.36M
est: 147.47M (+6.7%)
|
133.77M
est: 155.20M (-13.8%)
|
108.47M
est: 66.13M (+64.0%)
|
73.74M
est: 66.47M (+10.9%)
|
59.69M
est: 64.44M (-7.4%)
|
65.34M
est: 67.18M (-2.7%)
|
71.46M
est: 63.45M (+12.6%)
|
67.20M
est: 65.60M (+2.4%)
|
73.40M
est: 84.40M (-13.0%)
|
86.34M
86.34M – 86.34M
+2.3% YoY
|
92.51M
92.51M – 92.51M
+7.1% YoY
|
| EPS |
-6.09
est: 0.13 (-4,723.8%)
|
-0.33
est: 0.13 (-350.6%)
|
-0.08
est: 0.36 (-123.4%)
|
0.31
est: 0.51 (-39.5%)
|
-1.48
|
0.40
|
0.03
|
0.02
|
0.03
est: 0.04 (-33.8%)
|
-0.18
est: -0.07 (-157.1%)
|
0.04
est: -0.01 (+495.0%)
|
0.14
0.14 – 0.14
+1,500.0% YoY
|
0.26
0.26 – 0.26
+85.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 1.6K | 0.07% |
| 2 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 263.31 | 0.56% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anna Grabowska | Senior Finance Manager | — | female |
| Artur Mroz-Goncalves | Chief Executive Officer and Sales & Marketing Director at Bioton Marketing Agency (BMA) | — | male |
| Dariusz Gurtowski | Director of Science & Technology | — | male |
| Ewelina Romanska | Director of HR & Communication | — | female |
| Jeremy Launders | Chief Executive Officer & President of the Management Board | — | male |
| Kamila Musnicka | Director of Legal Department | — | female |
| Mateusz Patryk Kosecki | Head of Biolek Business Unit & Chief Executive Officer of Biolek Sp. Z O.O. | — | male |
| Michal Deptuch | Operations Director | — | male |
| Renata Prokopczyk | Chief Accountant | — | — |
| Romuald Apollo Harwas | Member of Management Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIO.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
